-
UPDATE: Eli Lilly Reports 11% Drop In Q2 Earnings
Thursday, July 21, 2011 - 7:06am | 89Eli Lilly & Co (NYSE: LLY) reported an 11% decline in its second-quarter earnings. LLY's quarterly net income dropped to $1.20 billion, or $1.07 per share, from $1.35 billion, or $1.22 per share, in the year-ago period. Its adjusted earnings dropped to $1.18 per share from $1.24 per share....
-
Deutsche Bank Updates 7/21/11
Thursday, July 21, 2011 - 6:35am | 663Deutsche Bank made a number of updates in a research report published today. Tractor Supply Co. (NASDAQ: TSCO) had its rating reiterated at Buy. At the same time, its price target was raised from $70 to $80. Johnson Controls (NYSE: JCI) had its rating reiterated at Hold...
-
US Stock Futures Down As Investors Await Earnings Reports
Thursday, July 21, 2011 - 6:28am | 608US stock futures are lower this morning, as investors are awaiting earnings reports. Futures on the Dow Jones Industrial Average dipped 25 points to 12,482.00 and futures on the S&P 500 stock index fell 3.90 points to 1,317.40. Nasdaq 100 futures dropped 10.25 points to 2,371.50. US stocks...
-
Earnings Scheduled For July 21
Thursday, July 21, 2011 - 3:30am | 479Advanced Micro Devices Inc (NYSE: AMD) is expected to report its Q2 EPS at $0.08 on revenue of $1.58 billion. Pepsico Inc (NYSE: PEP) is projected to report its Q2 EPS at $1.21 on revenue of $16.41 billion. Eli Lilly and Company (NYSE: LLY) is projected to report its Q2 EPS at $1.17 on revenue...
-
UPDATE: FDA Approves New Medicine BRILINTA For Use in the US
Wednesday, July 20, 2011 - 5:27pm | 314AstraZeneca (NYSE: AZN) announced today that the US Food and Drug Administration (FDA) has approved BRILINTA™ (ticagrelor) tablets to reduce the rate of heart attack (myocardial infarction and cardiovascular death in adult patients with acute coronary syndrome, compared to clopidogrel. BRILINTA,...
-
McNicoll, Lewis & Vlak Maintains SuperGen Buy, $8 PT
Wednesday, July 20, 2011 - 5:20pm | 95McNicoll, Lewis & Vlak maintained its SuperGen (NASDAQ: SUPG) Buy rating and $8 price target after SuperGen's acquisition announcement of Astex Therapeutics in a research report published today. In the report, MLV states, "We expect SuperGen to provide an update on corporate structure and...
-
AstraZeneca Spikes on Brilinta Approval Rumor, Continues to Rise Following FDA Confirmation
Wednesday, July 20, 2011 - 5:11pm | 97AstraZeneca (NYSE: AZN) spiked 1% this afternoon following rumors that Brilinta has received FDA approval. Benzinga then spoke with AstraZeneca, which said it had not yet received approval, but expected to soon. Moments later, the company announced that the FDA had now approved its anti-clotting...
-
AstraZeneca Says BRILINTA Not Yet Approved; Expecting Approval Decision Soon
Wednesday, July 20, 2011 - 4:32pm | 77After calling the company to confirm the earlier rumor posted here, a spokesperson for AstraZeneca (NYSE: AZN) says that BRILINTA has not yet received FDA approval. Nevertheless, the company "expects" approval soon, according to the call. AstraZeneca is currently trading at $50/share in post-market...
-
Lannett Receives FDA Approval for Phentermine HCl Capsules, 37.5 mg
Wednesday, July 20, 2011 - 3:33pm | 100Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) of Phentermine HCl Capsules, 37.5 mg. Phentermine HCl Capsules, 37.5 mg, is therapeutically equivalent to the reference listed...
-
Six Attractively Valued Dividend Growth Stocks Reporting Earnings!
Wednesday, July 20, 2011 - 3:13pm | 3247Investors today have instant access to minute by minute changes in the stock prices of their portfolio holdings in real time. Since stock prices tend to fluctuate wildly from one day to the next, I for one do not feel that this information overload is a good thing. What makes matters even worse is...
-
Morning Market Losers
Wednesday, July 20, 2011 - 10:07am | 129Dynavax Technologies Corporation (NASDAQ: DVAX) dipped 31.33% to $2.17 at 10:05 am. DVAX's cash, cash equivalents and marketable securities at June 30, 2011 came in at $61.7 million, versus $53.2 million at March 31, 2011. Icagen Inc (NASDAQ: ICGN) fell 23.10% to $5.96. Pfizer Inc (NYSE: PFE)...
-
Icagen Moving over 22% Lower after $6/Share Buyout Offer
Wednesday, July 20, 2011 - 9:11am | 241Pfizer Inc. (NYSE: PFE) and Icagen, Inc. (Nasdaq: ICGN) today announced that they have entered into a definitive merger agreement. Pfizer, which currently owns approximately 11% of Icagen's fully diluted shares, will acquire the remaining 8.3 million shares at a price of $6.00 per share. The...
-
Deutsche Bank Comments on Johnson & Johnson
Wednesday, July 20, 2011 - 9:02am | 142Deutsche Bank has published a report on Johnson & Johnson (NYSE: JNJ) maintaining a HOLD rating for the massive holding company. In the report, Deutsche Bank wrote, "J&J's 2Q11 sales were higher than expected mainly due to FX as underlying growth was similar to 1Q11 adjusting for easy...
-
Gabelli Maintains Earnings Estimates On Johnson & Johnson
Wednesday, July 20, 2011 - 8:59am | 113Gabelli & Co. is out with a research report on Johnson & Johnson (NYSE: JNJ) after it reported earnings yesterday. It has a Buy rating on shares. In a note to clients, Gabelli & Co. writes, "We see accelerating sales growth in the pharma and consumer business through 2012, with steady...
-
UPDATE: Abbott Laboratories Reports 50% Surge In Q2 Net Income, Raises FY11 Earnings Forecast
Wednesday, July 20, 2011 - 8:44am | 89Abbott Laboratories (NYSE: ABT) reported a 50% rise in its Q2 net income. ABT's quarterly earnings jumped to $1.94 billion, or $1.23 per share, from $1.29 billion, or $0.83 per share, in the year-ago period. Its adjusted earnings came in at $1.12 per share. ABT's revenue surged to $9.62 billion...